Patents by Inventor Vuong Trieu

Vuong Trieu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS
    Publication number: 20130244952
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 19, 2013
    Applicant: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • NANOPARTICLE FORMULATIONS AND USES THEREOF
    Publication number: 20130195983
    Abstract: The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.
    Type: Application
    Filed: April 9, 2010
    Publication date: August 1, 2013
    Inventors: Neil P. Desai, Chunlin Tao, Tapas De, Sherry Xiaopei Ci, Vuong Trieu
  • SPARC BINDING APTAMERS AND USES THEREOF
    Publication number: 20130195757
    Abstract: The invention relates to nucleic acid aptamers having the ability to bind human SPARC protein (osteonectin) with specificity. The invention also relates to compositions including such aptamers, as well as methods of identifying such aptamers. The invention further relates to methods for using such aptamers in treating and diagnosing proliferative diseases such as, e.g., cancer.
    Type: Application
    Filed: May 2, 2011
    Publication date: August 1, 2013
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Kouros Motamed, Yanshan Dai, Vuong Trieu, Neil Desai
  • SPARC binding peptides and uses thereof
    Patent number: 8445637
    Abstract: Disclosed are SPARC and albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents In particular, compositions comprising SPARC binding peptide—Antibody Fc domain fusion proteins and methods of their use are disclosed.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: May 21, 2013
    Assignee: Abraxis BioScience, LLC
    Inventor: Vuong Trieu
  • SPARC BINDING ANTIBODIES AND USES THEREOF
    Publication number: 20130101504
    Abstract: The invention provides SPARC binding antibodies that target disease sites, in particular, tumors and uses thereof to diagnose and treat diseases, in particular, cancerous tumors.
    Type: Application
    Filed: April 26, 2011
    Publication date: April 25, 2013
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Vuong Trieu, Xiping Liu, Neil Desai
  • SPARC and methods of use thereof
    Patent number: 8420603
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: April 16, 2013
    Assignee: Abraxis BioScience, LLC
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • Sparc and methods of use thereof
    Patent number: 8415304
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: April 9, 2013
    Assignee: Abraxis BioScience, LLC
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy
    Patent number: 8383358
    Abstract: The invention provides anti-SPARC antibody-based techniques for predicting a response to chemotherapy.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: February 26, 2013
    Assignee: Abraxis BioScience, LLC
    Inventors: Vuong Trieu, Neil Desai, Daniel Knauer
  • Compositions and methods of delivery of pharmacological agents
    Patent number: 8314156
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: November 20, 2012
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS
    Publication number: 20120283205
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Application
    Filed: February 7, 2012
    Publication date: November 8, 2012
    Inventors: Neil P. DESAI, Patrick Soon-Shiong, Vuong Trieu
  • USE OF THE SPARC MICROENVIRONMENT SIGNATURE IN THE TREATMENT OF CANCER
    Publication number: 20120245089
    Abstract: The invention provides multiparametric anti-SPARC antibody-based techniques for predicting the response to therapy, including chemotherapy, radiotherapy, surgical therapy and combination therapies
    Type: Application
    Filed: September 20, 2010
    Publication date: September 27, 2012
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Vuong Trieu, Neil Desai
  • COMBINATION THERAPY WITH THIOCOLCHICINE DERIVATIVES
    Publication number: 20120189701
    Abstract: The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a colchicine or thiocolchicine dimer and an anti-VEGF antibody. The method may further comprise administering an effective amount of a taxane. The colchicine or thiocolchicine dimer and the taxane (such as paclitaxel) may be present in the form of nanoparticles, such as nanoparticles comprising the drug and a carrier protein such as albumin.
    Type: Application
    Filed: March 12, 2010
    Publication date: July 26, 2012
    Inventors: Neil P. Desai, Vuong Trieu
  • SPARC ANTISENSE COMPOSITIONS AND USES THEREOF
    Publication number: 20120183538
    Abstract: The invention provides SPARC antisense oligonucleotides and methods of their use in proliferative diseases such as cancer and hepatic fibrosis.
    Type: Application
    Filed: July 9, 2010
    Publication date: July 19, 2012
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Vuong Trieu, Larn Hwang, Neil Desai
  • COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY
    Publication number: 20120128732
    Abstract: The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that inhibits a pro survival and/or inflammatory signal.
    Type: Application
    Filed: December 11, 2009
    Publication date: May 24, 2012
    Inventors: Vuong Trieu, Osmond D'Cruz, Neil P. Desai
  • SPARC ANGIOGENIC DOMAIN AND METHODS OF USE
    Publication number: 20120087910
    Abstract: The invention provides compositions and methods which exploit the discovery of the SPARC carboxy angiogenic domain.
    Type: Application
    Filed: March 11, 2010
    Publication date: April 12, 2012
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Vuong Trieu, Daniel Knauer, Neil Desai
  • Compositions and methods of delivery of pharmacological agents
    Patent number: 8138229
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: March 20, 2012
    Assignee: Abraxis Bioscience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • PERIPHERAL BLOOD SPARC BINDING ANTIBODIES AND USES THEREOF
    Publication number: 20120052007
    Abstract: The invention provides SPARC binding antibodies that have high affinity to SPARC, particularly plasma SPARC, and methods of using such antibodies in treating conditions including cancer.
    Type: Application
    Filed: June 3, 2011
    Publication date: March 1, 2012
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Vuong Trieu, Xiping Liu, Neil Desai
  • SPARC binding peptides and uses thereof
    Publication number: 20120039801
    Abstract: Disclosed are SPARC and albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents In particular, compositions comprising SPARC binding peptide—Antibody Fc domain fusion proteins and methods of their use are disclosed.
    Type: Application
    Filed: December 7, 2009
    Publication date: February 16, 2012
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventor: Vuong Trieu
  • USE OF THE SPARC MICROENVIRONMENT SIGNATURE IN THE TREATMENT OF CANCER
    Publication number: 20120020959
    Abstract: The invention provides multiparametric anti-SPARC antibody-based techniques for predicting the response to chemotherapy.
    Type: Application
    Filed: June 3, 2011
    Publication date: January 26, 2012
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Vuong Trieu, Xiping Liu, Neil Desai
  • SPARC BINDING SCFVS
    Publication number: 20120014954
    Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.
    Type: Application
    Filed: December 7, 2009
    Publication date: January 19, 2012
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventor: Vuong Trieu